Pfizer and BioNTech have reported that early trial data showed their vaccine to be more than 90 percent effective. What comes next for Pfizer and this vaccine, and what makes it different from dozens of other vaccines in the pipeline? Susan Ellenberg, PhD, comments.
To understand health and disease today, we need new thinking and novel science —the kind we create when multiple disciplines work together from the ground up. That is why this department has put forward a bold vision in population-health science: a single academic home for biostatistics, epidemiology and informatics. LEARN MORE ABOUT US